May 03, 2016 10:55 AM ET

Life Sciences Tools and Services

Company Overview of Aegis Therapeutics, LLC

Company Overview

Aegis Therapeutics, LLC, a drug-delivery and drug-formulation technologies company, commercializes drug delivery and protein stabilization technologies to pharmaceutical and biopharmaceutical companies. It offers Intravail, a drug delivery technology that enables the non-invasive delivery of a broad range of protein, peptide, and non-peptide drugs. The company also provides ProTek to create homogeneous, stable, aqueous or lyophilized dosage forms for peptide or protein therapeutics. In addition, it offers Hydrogels, an absorption-enhancing self-assembling aqueous hydrogels for transdermal drug delivery or transmucosal application. The company was founded in 2003 and is based in San Diego, Ca...

11770 Bernardo Plaza Court

Suite 353

San Diego, CA 92128

United States

Founded in 2003





Key Executives for Aegis Therapeutics, LLC

Chief Executive Officer and Director
Executive Chairman
Age: 73
Chief Business Officer and Director
Member of Advisory Board
Compensation as of Fiscal Year 2015.

Aegis Therapeutics, LLC Key Developments

Dauntless Pharmaceuticals Announces Licensing Agreement with Aegis Therapeutics

Dauntless Pharmaceuticals Inc. and Aegis Therapeutics, LLC have announced a licensing agreement providing Dauntless access to Aegis' Intravail (R) drug delivery technology for an undisclosed oncology application and an option for three additional drugs. Both the companies based in the US.

Aegis Offers Exclusive License to Develop, Commercialize, and Sell its Patented Non-Invasive Exenatide Metered Nasal Spray Diabetes Drug

Aegis announced that it is offering an exclusive license to develop, commercialize, and sell its patented non-invasive exenatide metered nasal spray diabetes drug. Exenatide is a 39-amino acid synthetic peptide GLP-1 analog highly effective in controlling blood glucose levels in Type-2 diabetes. All currently available GLP-1 analogs require injection. The currently marketed injectable form of exenatide, sold under the trademark Byetta(R), requires twice daily injections. The Aegis patented Intravail(R) based formulation of exenatide provides equivalent blood levels using a simple metered nasal spray to replace each of the two daily injections. The total market for GLP-1 analogs is expected to grow to $5 billion within the next few years. As the only non-injectable option for patients seeking to avoid needles, needlestick injuries, and syringe disposal problems, the non-injectable Aegis nasal spray exenatide formulation is poised to achieve significant market share.

Aegis Therapeutics, LLC Presents at BIO International Convention, Jun-25-2014 04:15 PM

Aegis Therapeutics, LLC Presents at BIO International Convention, Jun-25-2014 04:15 PM. Venue: San Diego Convention Center, San Diego, California, United States.

Similar Private Companies By Industry

Company Name Region
Tigermed-BDM Inc. United States
Radiant Development United States
Biomatrica, Inc. United States
InDevR, Inc. United States
Acupac Packaging, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Aegis Therapeutics, LLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at